@article{e8b0d8166ab04f3aaf6ae00d90a31cfd,
title = "Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging",
abstract = "Background: Advanced magnetic resonance imaging (MRI) methods can provide more specific information about various microstructural tissue changes in multiple sclerosis (MS) brain. Quantitative measurement of T1 and T2 relaxation, and diffusion basis spectrum imaging (DBSI) yield metrics related to the pathology of neuroinflammation and neurodegeneration that occurs across the spectrum of MS. Objective: To use relaxation and DBSI MRI metrics to describe measures of neuroinflammation, myelin and axons in different MS subtypes. Methods: 103 participants (20 clinically isolated syndrome (CIS), 33 relapsing-remitting MS (RRMS), 30 secondary progressive MS and 20 primary progressive MS) underwent quantitative T1, T2, DBSI and conventional 3T MRI. Whole brain, normal-appearing white matter, lesion and corpus callosum MRI metrics were compared across MS subtypes. Results: A gradation of MRI metric values was seen from CIS to RRMS to progressive MS. RRMS demonstrated large oedema-related differences, while progressive MS had the most extensive abnormalities in myelin and axonal measures. Conclusion: Relaxation and DBSI-derived MRI measures show differences between MS subtypes related to the severity and composition of underlying tissue damage. RRMS showed oedema, demyelination and axonal loss compared with CIS. Progressive MS had even more evidence of increased oedema, demyelination and axonal loss compared with CIS and RRMS.",
keywords = "T relaxation, T relaxation, brain, diffusion basis spectrum imaging, multiple sclerosis",
author = "Vavasour, {Irene M.} and Peng Sun and Carina Graf and Yik, {Jackie T.} and Kolind, {Shannon H.} and Li, {David K.B.} and Roger Tam and Sayao, {Ana Luiza} and Alice Schabas and Virginia Devonshire and Robert Carruthers and Anthony Traboulsee and Moore, {GR Wayne} and Song, {Sheng Kwei} and Cornelia Laule",
note = "Funding Information: The authors thank the study participants, the UBC MS clinic staff and the MRI technologists at the UBC MRI Research Centre. They gratefully acknowledge the support of Philips Healthcare. Funding Information: The authors thank the study participants, the UBC MS clinic staff and the MRI technologists at the UBC MRI Research Centre. They gratefully acknowledge the support of Philips Healthcare. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Multiple Sclerosis Society of Canada (grant number: 2302) Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: I.M.V., P.S., C.G. and J.T.Y. have nothing to disclose. S.H.K. has received research support from Roche, Genzyme, the MS Society of Canada, NSERC, VCHRI, MSFHR and Milan & Maureen Ilich Foundation; consulting for Novartis. D.K.B.L. has received research funding from the Multiple Sclerosis Society of Canada. He is Emeritus Director of the UBC MS/MRI Research Group that has been contracted to perform central analysis of MRI scans for therapeutic trials with Roche and Sanofi-Genzyme. The UBC MS/MRI Research Group has also received grant support for investigator-initiated studies from Genzyme, Novartis and Roche. He has been a consultant to Vertex Pharmaceuticals and Genzyme, served on the Scientific Advisory Board for Celgene and the PML-MS Steering Committee for Biogen He has given lectures, supported by non-restricted education grants from Academy of Health Care Learning, Consortium of MS Centers and Sanofi-Genzyme. R.T. has received grant funding from NSERC, MS Society of Canada, and Mitacs, and research support as part of sponsored clinical studies from Novartis, Roche, and Sanofi-Genzyme. A.-L.S. has received speaking honoraria from Biogen and Merck-Serono. She has participated in Ad-boards for Biogen, Teva, Roche, Novartis, Sanofi-Genzyme and Merck-Serono. AS has received honoraria from Teva, Biogen, and Sanofi-Genzyme, Novartis, Roche, EMD Serono and Biogen. V.D. has received honorarium from Sanofi, MD Serono, Biogen and Roche. R.C. is site investigator for studies funded by Roche, Novartis, MedImmune and EMD Serono and receives research support from Teva Innovation Canada, Roche Canada and Vancouver Coastal Health Research Institute. R.C. has received honoraria from Roche, EMD Serono, Sanofi, Biogen, Novartis and Teva. A.T. has received research funding from MS Society of Canada, Roche and Sanofi-Genzyme; received honoraria or travel support from Consortium of MS Centers, Biogen, Teva, Roche, Merck/EMD Serono and Sanofi-Genzyme. G.R.W.M. has received funding support from the Multiple Sclerosis Society of Canada and the International Collaboration on Repair Discoveries. S.-K.S. and/or W.U. has a financial (ownership) interest in Cancer Research LLC and may financially benefit if the company is successful in marketing its product(s) that is/are related to this research. C.L. has research support from Natural Sciences and Engineering Research Council of Canada, the MS Society of Canada and the International Collaboration on Repair Discoveries. Publisher Copyright: {\textcopyright} The Author(s), 2021.",
year = "2022",
month = mar,
doi = "10.1177/13524585211023345",
language = "English",
volume = "28",
pages = "418--428",
journal = "Multiple Sclerosis",
issn = "1352-4585",
number = "3",
}